Autoimmunity After Checkpoint Blockade
Launched by UNIVERSITY OF PENNSYLVANIA · Oct 7, 2019
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating why some cancer patients who receive a specific type of treatment called immune checkpoint inhibitors (ICIs) develop autoimmune problems. Autoimmunity is when the body’s immune system mistakenly attacks its own healthy cells. The study aims to understand the genetic and immune system factors that contribute to these immune-related side effects in patients undergoing cancer treatment.
To participate in this trial, you need to have a cancer diagnosis and be prescribed an immune checkpoint inhibitor. The trial is open to adults aged 65 and older, but unfortunately, children under 18 and individuals with a history of organ transplants cannot take part. If you join the study, you can expect to provide information about your health and undergo some assessments to help researchers learn more about the immune system's response to cancer treatment. This study is important as it may help improve future cancer therapies and reduce the risk of these side effects for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A diagnosis of cancer and prescription for a checkpoint inhibitor
- Exclusion Criteria:
- • Any subjects not willing or able to give consent
- • Children under the age of 18
- • A history of transplant
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Sokratis Apostolidis, MD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials